Robert T Naismith1, Robert A Bermel2, Christopher S Coffey2, Andrew D Goodman2, Janel Fedler2, Marianne Kearney2, Eric C Klawiter2, Kunio Nakamura2, Sridar Narayanan2, Christopher Goebel2, Jon Yankey2, Elizabeth Klingner2, Robert J Fox2. 1. From Washington University (R.T.N.), St. Louis, MO; Cleveland Clinic Foundation (R.A.B., K.N., C.G., R.J.F.), OH; University of Iowa (C.S.C., J.F., J.Y., E.K.), Iowa City; University of Rochester (A.D.G.), NY; Massachusetts General Hospital (M.K., E.C.K.), Harvard Medical School, Boston; McConnell Brain Imaging Centre (S.N.), Montreal Neurological Institute, McGill University; and NeuroRx Research (S.N.), Montreal, Canada. naismithr@wustl.edu. 2. From Washington University (R.T.N.), St. Louis, MO; Cleveland Clinic Foundation (R.A.B., K.N., C.G., R.J.F.), OH; University of Iowa (C.S.C., J.F., J.Y., E.K.), Iowa City; University of Rochester (A.D.G.), NY; Massachusetts General Hospital (M.K., E.C.K.), Harvard Medical School, Boston; McConnell Brain Imaging Centre (S.N.), Montreal Neurological Institute, McGill University; and NeuroRx Research (S.N.), Montreal, Canada.
Abstract
OBJECTIVE: To determine whether ibudilast has an effect on brain volume and new lesions in progressive forms of multiple sclerosis (MS). METHODS: A randomized, placebo-controlled, blinded study evaluated ibudilast at a dose of up to 100 mg over 96 weeks in primary and secondary progressive MS. In this secondary analysis of a previously reported trial, secondary and tertiary endpoints included gray matter atrophy, new or enlarging T2 lesions as measured every 24 weeks, and new T1 hypointensities at 96 weeks. Whole brain atrophy measured by structural image evaluation, using normalization, of atrophy (SIENA) was a sensitivity analysis. RESULTS: A total of 129 participants were assigned to ibudilast and 126 to placebo. New or enlarging T2 lesions were observed in 37.2% on ibudilast and 29.0% on placebo (p = 0.82). New T1 hypointense lesions at 96 weeks were observed in 33.3% on ibudilast and 23.5% on placebo (p = 0.11). Gray matter atrophy was reduced by 35% for those on ibudilast vs placebo (p = 0.038). Progression of whole brain atrophy by SIENA was slowed by 20% in the ibudilast group compared with placebo (p = 0.08). CONCLUSION: Ibudilast treatment was associated with a reduction in gray matter atrophy. Ibudilast treatment was not associated with a reduction in new or enlarging T2 lesions or new T1 lesions. An effect on brain volume contributes to prior data that ibudilast appears to affect markers associated with neurodegenerative processes, but not inflammatory processes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for people with MS, ibudilast does not significantly reduce new or enlarging T2 lesions or new T1 lesions.
OBJECTIVE: To determine whether ibudilast has an effect on brain volume and new lesions in progressive forms of multiple sclerosis (MS). METHODS: A randomized, placebo-controlled, blinded study evaluated ibudilast at a dose of up to 100 mg over 96 weeks in primary and secondary progressive MS. In this secondary analysis of a previously reported trial, secondary and tertiary endpoints included gray matter atrophy, new or enlarging T2 lesions as measured every 24 weeks, and new T1 hypointensities at 96 weeks. Whole brain atrophy measured by structural image evaluation, using normalization, of atrophy (SIENA) was a sensitivity analysis. RESULTS: A total of 129 participants were assigned to ibudilast and 126 to placebo. New or enlarging T2 lesions were observed in 37.2% on ibudilast and 29.0% on placebo (p = 0.82). New T1 hypointense lesions at 96 weeks were observed in 33.3% on ibudilast and 23.5% on placebo (p = 0.11). Gray matter atrophy was reduced by 35% for those on ibudilast vs placebo (p = 0.038). Progression of whole brain atrophy by SIENA was slowed by 20% in the ibudilast group compared with placebo (p = 0.08). CONCLUSION: Ibudilast treatment was associated with a reduction in gray matter atrophy. Ibudilast treatment was not associated with a reduction in new or enlarging T2 lesions or new T1 lesions. An effect on brain volume contributes to prior data that ibudilast appears to affect markers associated with neurodegenerative processes, but not inflammatory processes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for people with MS, ibudilast does not significantly reduce new or enlarging T2 lesions or new T1 lesions.
Authors: Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: Lucien C D Gibson; Stuart F Hastings; Ian McPhee; Robert A Clayton; Claire E Darroch; Alison Mackenzie; Fiona L Mackenzie; Michiaki Nagasawa; Patricia A Stevens; Simon J Mackenzie Journal: Eur J Pharmacol Date: 2006-03-13 Impact factor: 4.432
Authors: Zografos Caramanos; Vladimir S Fonov; Simon J Francis; Sridar Narayanan; G Bruce Pike; D Louis Collins; Douglas L Arnold Journal: Neuroimage Date: 2009-08-12 Impact factor: 6.556
Authors: Anand J C Eijlers; Quinten van Geest; Iris Dekker; Martijn D Steenwijk; Kim A Meijer; Hanneke E Hulst; Frederik Barkhof; Bernard M J Uitdehaag; Menno M Schoonheim; Jeroen J G Geurts Journal: Brain Date: 2018-09-01 Impact factor: 13.501
Authors: Ernst-Wilhelm Radue; Till Sprenger; Laura Gaetano; Nicole Mueller-Lenke; Steve Cavalier; Karthinathan Thangavelu; Michael A Panzara; Jessica E Donaldson; Fiona M Woodward; Jens Wuerfel; Jerry S Wolinsky; Ludwig Kappos Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-08-09
Authors: D H Miller; D Soon; K T Fernando; D G MacManus; G J Barker; T A Yousry; E Fisher; P W O'Connor; J T Phillips; C H Polman; L Kappos; M Hutchinson; E Havrdova; F D Lublin; G Giovannoni; A Wajgt; R Rudick; F Lynn; M A Panzara; A W Sandrock Journal: Neurology Date: 2007-04-24 Impact factor: 9.910
Authors: Douglas L Arnold; Elizabeth Fisher; Vesna V Brinar; Jeffrey A Cohen; Alasdair J Coles; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Miroslav Stojanovic; Howard L Weiner; Stephen L Lake; David H Margolin; David R Thomas; Michael A Panzara; D Alastair S Compston Journal: Neurology Date: 2016-09-02 Impact factor: 9.910
Authors: Robert J Fox; Paola Raska; Christian Barro; Matthew Karafa; Victoria Konig; Robert A Bermel; Marianne Chase; Christopher S Coffey; Andrew D Goodman; Eric C Klawiter; Robert T Naismith; Jens Kuhle Journal: Mult Scler Date: 2021-02-26 Impact factor: 6.312
Authors: Andrew D Goodman; Janel K Fedler; Jon Yankey; Elizabeth A Klingner; Dixie J Ecklund; Christopher V Goebel; Robert A Bermel; Marianne Chase; Christopher S Coffey; Eric C Klawiter; Robert T Naismith; Robert J Fox Journal: Ann Clin Transl Neurol Date: 2021-01-18 Impact factor: 4.511
Authors: Alan J Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J Fox; Anne Helme; Reinhard Hohlfeld; Robert Hyde; Pamela Kanellis; Douglas Landsman; Catherine Lubetzki; Ruth Ann Marrie; Julia Morahan; Xavier Montalban; Bruno Musch; Sarah Rawlings; Marco Salvetti; Finn Sellebjerg; Caroline Sincock; Kathryn E Smith; Jon Strum; Paola Zaratin; Timothy Coetzee Journal: Mult Scler Date: 2021-12-01 Impact factor: 6.312
Authors: Aref-Ali Gharooni; Brian K Kwon; Michael G Fehlings; Timothy F Boerger; Ricardo Rodrigues-Pinto; Paul Aarne Koljonen; Shekar N Kurpad; James S Harrop; Bizhan Aarabi; Vafa Rahimi-Movaghar; Jefferson R Wilson; Benjamin M Davies; Mark R N Kotter; James D Guest Journal: Global Spine J Date: 2022-02
Authors: Stanley L Cohan; Ralph H B Benedict; Bruce A C Cree; John DeLuca; Le H Hua; Jerold Chun Journal: CNS Drugs Date: 2022-06-20 Impact factor: 6.497
Authors: Douglas L Arnold; Daniela Piani-Meier; Amit Bar-Or; Ralph Hb Benedict; Bruce Ac Cree; Gavin Giovannoni; Ralf Gold; Patrick Vermersch; Sophie Arnould; Frank Dahlke; Thomas Hach; Shannon Ritter; Göril Karlsson; Ludwig Kappos; Robert J Fox Journal: Mult Scler Date: 2022-03-09 Impact factor: 5.855